1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. ONKURE THERAPEUTICS INC. - ORDINARY SHARES - CLASS A

OnKure Therapeutics Inc. - Ordinary Shares - Class A

XNAS: OKUR

Download real time

2.27 0.07 (3.18%)

New 52W Low in past week

570.9K XNAS Volume

High volume today

XNAS 20 May, 2025 1:15 PM (EDT)

Watchlist

Portfolio

Share
10S
11W
3O
1T
30.7

Market Cap

Below industry Median
-0.4

PE TTM

Negative PE TTM
0

PEG TTM

0.3

Price to Book

Low in industry
-

Beta 1Year

Board Meeting
The next board meeting for OnKure Therapeutics Inc. - Ordinary Shares - Class A is on 30 May 2025 for the purpose of OnKure Therapeutics Inc First Quarter Earnings Results for 2025 See details


Insider Trading disclosures for OnKure Therapeutics Inc. - Ordinary Shares - Class A

The latest disclosure was made by Jason A. Leverone in OnKure Therapeutics Inc. - Ordinary Shares - Class A where a trade of 1,278 Class A Common Stock done at an average price of $3.3 was reported to US exchanges on April 4, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Jason A. Leverone Chief Financial Officer Sale of securities on an exchange or to another person at price $ 3.33 per share. 04 Apr 2025 1,278 15,053 - 3.3 4,253 Class A Common Stock
Jason A. Leverone Chief Financial Officer Sale of securities on an exchange or to another person at price $ 2.67 per share. 04 Apr 2025 1,844 13,209 - 2.7 4,925 Class A Common Stock
Nicholas A. Saccomano Director, President and CEO Sale of securities on an exchange or to another person at price $ 2.67 per share. 04 Apr 2025 516 3,682 - 2.7 1,378 Class A Common Stock
Nicholas A. Saccomano Director, President and CEO Sale of securities on an exchange or to another person at price $ 3.33 per share. 04 Apr 2025 358 4,198 - 3.3 1,191 Class A Common Stock
Isaac Manke Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Mar 2025 3,469 3,469 - 0 Class A Common Stock
Edward T. Mathers Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Mar 2025 2,580 2,580 - 0 Class A Common Stock
Dylan Hartley Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2025 45,000 45,000 - - Employee Stock Option (right to buy)
Samuel Agresta Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2025 45,000 45,000 - - Employee Stock Option (right to buy)
Jason A. Leverone Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2025 65,000 65,000 - - Employee Stock Option (right to buy)
Nicholas A. Saccomano Director, President and CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 27 Jan 2025 130,000 130,000 - - Employee Stock Option (right to buy)
Samuel Agresta Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 131,396 131,396 - - Employee Stock Option (right to buy)
Dylan Hartley Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 137,603 137,603 - - Employee Stock Option (right to buy)
Valerie Malyvanh Jansen Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 15,300 15,300 - - Stock Option (right to buy)
Andrew Phillips Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 15,300 15,300 - - Stock Option (right to buy)
Isaac Manke Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 15,300 15,300 - - Stock Option (right to buy)
Samuel Agresta Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 18,588 18,588 - - Employee Stock Option (right to buy)
Edward T. Mathers Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 15,300 15,300 - - Stock Option (right to buy)
Jason A. Leverone Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 5,781 5,781 - - Employee Stock Option (right to buy)
Jason A. Leverone Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 5,322 5,322 - - Employee Stock Option (right to buy)
Jason A. Leverone Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 130,611 130,611 - - Employee Stock Option (right to buy)
Jason A. Leverone Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 16,331 16,331 - - Class A Common Stock
Nicholas A. Saccomano Director, President and CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 8,449 8,449 - - Employee Stock Option (right to buy)
Nicholas A. Saccomano Director, President and CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 16,898 16,898 - - Employee Stock Option (right to buy)
Nicholas A. Saccomano Director, President and CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 1,485 1,485 - - Employee Stock Option (right to buy)
Nicholas A. Saccomano Director, President and CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 2,359 2,359 - - Employee Stock Option (right to buy)
Nicholas A. Saccomano Director, President and CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 4,556 4,556 - - Class A Common Stock
Nicholas A. Saccomano Director, President and CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 542,232 542,232 - - Employee Stock Option (right to buy)
R. Michael Carruthers Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 874 874 - - Class A Common Stock
R. Michael Carruthers Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 15,300 15,300 - - Stock Option (right to buy)
R. Michael Carruthers Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 1,324 1,324 - - Stock Option (right to buy)
R. Michael Carruthers Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 1,760 1,760 - - Stock Option (right to buy)
R. Michael Carruthers Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 04 Oct 2024 4,065 4,939 - - Class A Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters